Martin Turner qualified in Medicine from University of Cambridge and St. George’s Hospital Medical School London and trained in Neurology in London and Oxford. He is Professor of Clinical Neurology & Neuroscience within Oxford University’s Nuffield Department of Clinical Neurosciences, and Consultant Neurologist to the John Radcliffe Hospital in Oxford. His PhD, under the supervision of Professor Leigh at King’s College London, applied ligand PET to explore the then emerging concept of brain pathology in sporadic and familial cases of MND. His subsequent research has been in the development of biomarkers from neuroimaging (MRI and MEG) and biofluid assays, to accelerate therapy discovery. He has been the recipient of both Medical Research Council Clinician Scientist and Senior Clinical Fellowships, the ENCALS Investigator Award and the Royal College of Physicians Graham Bull Prize. He chairs the Research Committee of the Association of British Neurologists.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.